



Announcement Summary

Entity name

ARGENT BIOPHARMA LIMITED

Date of this announcement

Tuesday July 14, 2026

The +securities the subject of this notification are:

Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
RGTAAA	CONVERTIBLE NOTES	385,000	14/07/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ARGENT BIOPHARMA LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

116800269

1.3 ASX issuer code

RGT

1.4 The announcement is

New announcement

1.5 Date of this announcement

14/7/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

Other

Please specify

Issue of Convertible Notes. Refer to ASX Announcement dated 14 July 2026.

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class

ASX +security code and description

RGTAAA : CONVERTIBLE NOTES

Date the +securities the subject of this notification were issued

14/7/2026

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Any other information the entity wishes to provide about the +securities the subject of this notification

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Agreement to issue occurred concurrently with the issue date, as such, no appendix 3B was lodged.

Issue details

Number of +securities

385,000

Were the +securities issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Refer to announcement dated 14 July 2026.

Purpose of the issue

To raise additional working capital





Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
RGT : ORDINARY FULLY PAID	116,609,584

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
RGTAO : WARRANTS EXPIRING 16-JAN-2028 EX USD 0.55	2,500,000
RGTAAC : OPTION EXPIRING 20-MAR-2029 EX \$0.20	2,100,000
RGTAAM : OPTION EXPIRING 28-MAR-2027 EX \$0.42	240,000
RGTAAI : OPTION EXPIRING 31-JUL-2026 EX \$3.00	181,422
RGTAAL : OPTION EXPIRING 10-JAN-2027 EX \$1.00	740,000
RGTAAB : OPTION EXPIRING 01-APR-2029 EX \$0.70	724,000
RGTAO : WARRANTS EXPIRING 17-JUL-2027 EX USD 1.20	1,250,000
RGTAAP : WARRANT EXPIRING 23-APR-2028 EX USD 0.40	5,500,000
RGTAAQ : OPTION EXPIRING 23-APR-2032 EX USD 0.20	16,500,000
RGTAAN : WARRANTS EXPIRING 03-JUL-2027 EX USD 1.20	312,500
RGTAG : PERFORMANCE RIGHTS	20,100,000
RGTAAA : CONVERTIBLE NOTES	8,967,532
RGTA AJ : OPTION EXPIRING 07-NOV-2028 EX US\$0.32	15,500,000
RGTA AH : OPTION EXPIRING 14-JUL-2026 EX GBP 1.2	540,668
RGTA A : OPTION EXPIRING 03-DEC-2028 EX \$0.1025	21,950,952



RGTAAK : OPTION EXPIRING 01-DEC-2028 EX \$0.86

288,185



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

385,000 Convertible Notes.

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

N/A